Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Microbot Medical Inc (MBOT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$1.07-6.14%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MBOT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain ATM program for capital raising | The company aims to maintain its capital raising program to fund growth. | Intact | ATM program is suspended or materially reduced | ATM program active (no suspension reported) April 2026 filing confirms the ATM program is active. No news of suspension or reduction. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth thesis centered on expanding use of the LIBERTY System, not a proven profitable business. The thesis is in a watch state: commercial activity is advancing, while recent financial performance remains weak and overall risk is high.
The valuation is expensive versus peers, with a 69.27% premium, and model confidence is low. The premium appears tied to optionality, meaning the market is assigning value to possible future growth, but the evidence does not show that this potential has yet produced strong financial results.
Near term, revenue rose from $105,000 in Q1 2026 to $241,000 in Q2, alongside reported procedure growth and an October OBL customer announcement. But gross profit was negative in Q2 and the operating loss widened, so cost reductions have yet to show clear results; establishing a second manufacturing site also remains in implementation. Near-term risk includes weaker employment data and mixed results from large Healthcare companies, while the current miss-risk assessment is described as quiet.
Over the multi-year view, the central question is whether LIBERTY adoption and use can keep expanding enough to support stronger financial performance. Progress also depends on reducing cost of revenue and showing that the second manufacturing site delivers useful capacity or cost results. In the near term, continued strength from sector bellwethers ABT, MDT, and SYK could support the Healthcare backdrop, while weaker employment data or lower guidance from those companies could weaken it.
For the next 1 to 3 years, MBOT remains a high-risk, loss-making growth story with early signs of commercial expansion but limited proof of improving economics. The thesis hinges on turning adoption into sustained financial progress. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Microbot Medical Inc's published investment case. The stated target is EPS no worse than -$0.32 in FY27. |
| Improving |
| EPS deteriorates beyond -$0.32 in FY27 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth to support business scaling | A primary condition in Microbot Medical Inc's published investment case. The stated target is >= $10.6M revenue in FY27. | Broken | revenue falls below $3.45M in FY26 or fails to grow toward $10.6M in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.30 → $-0.32 · observed estimates
$0.01B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-07-25 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-07-26 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-07-27 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-07-28 | $-0.30 | $10,600,000 | 3 / 2 |
| 2026-07-29 | $-0.30 | $10,600,000 | 3 / 2 |
| 2026-07-30 | $-0.30 | $10,600,000 | 3 / 2 |
| 2026-07-31 | $-0.30 | $10,600,000 | 3 / 2 |
| 2026-08-01 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-08-02 | $-0.30 | $10,600,000 | 3 / 2 |
| 2026-08-03 | $-0.30 | $10,600,000 | 3 / 2 |
| 2026-08-04 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-08-05 | $-0.30 | $10,600,000 | 3 / 2 |
| 2026-08-06 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-08-07 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-08-08 | $-0.30 | $10,600,000 | 3 / 2 |
| 2026-08-09 | $-0.30 | $10,600,000 | 3 / 2 |
| 2026-08-10 | $-0.30 | $10,600,000 | 3 / 2 |
| 2026-08-12 | $-0.30 | $10,600,000 | 3 / 2 |
| 2026-08-13 | $-0.30 | $10,600,000 | 3 / 2 |
| 2026-08-14 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-08-15 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-08-16 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-08-17 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-08-18 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-08-19 | $-0.30 | $8,900,000 | 2 / 2 |
| 2026-08-20 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-08-21 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-08-22 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-08-23 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-08-24 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-08-25 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-08-26 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-08-27 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-08-28 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-08-29 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-08-30 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-08-31 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-09-01 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-09-02 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-09-03 | $-0.34 | $7,766,667 | 2 / 2 |
| 2026-09-04 | $-0.34 | $7,766,667 | 2 / 1 |
| 2026-09-05 | $-0.34 | $7,766,667 | 2 / 1 |
| 2026-09-06 | $-0.34 | $7,766,667 | 2 / 1 |
| 2026-09-07 | $-0.34 | $7,766,667 | 2 / 1 |
| 2026-09-08 | $-0.34 | $7,766,667 | 2 / 1 |
| 2026-09-09 | $-0.34 | $7,766,667 | 2 / 1 |
| 2026-09-10 | $-0.34 | $7,766,667 | 2 / 1 |
| 2026-09-11 | $-0.34 | $7,766,667 | 2 / 1 |
| 2026-09-12 | $-0.29 | $6,426,667 | 2 / 1 |
| 2026-09-13 | $-0.29 | $6,426,667 | 2 / 1 |
| 2026-09-14 | $-0.29 | $6,426,667 | 2 / 1 |
| 2026-09-15 | $-0.29 | $6,426,667 | 2 / 1 |
| 2026-09-16 | $-0.29 | $6,426,667 | 2 / 1 |
| 2026-09-17 | $-0.29 | $6,426,667 | 2 / 2 |
| 2026-09-18 | $-0.29 | $6,426,667 | 2 / 2 |
| 2026-09-19 | $-0.29 | $6,426,667 | 2 / 2 |
| 2026-09-20 | $-0.29 | $6,426,667 | 2 / 2 |
| 2026-09-21 | $-0.29 | $6,426,667 | 2 / 2 |
| 2026-09-22 | $-0.29 | $6,426,667 | 2 / 2 |
| 2026-09-23 | $-0.29 | $6,426,667 | 2 / 2 |
| 2026-09-24 | $-0.29 | $6,426,667 | 2 / 2 |
| 2026-09-25 | $-0.29 | $6,426,667 | 2 / 2 |
| 2026-09-26 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-09-27 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-09-28 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-09-29 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-09-30 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-01 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-02 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-03 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-04 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-05 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-06 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-07 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-08 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-09 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-10 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-11 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-12 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-13 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-14 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-15 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-16 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-17 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-18 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-19 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-20 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-21 | $-0.30 | $5,093,333 | 2 / 2 |
| 2026-10-22 | $-0.31 | $4,010,000 | 2 / 2 |
| 2026-10-23 | $-0.31 | $4,010,000 | 2 / 2 |
| 2026-10-24 | $-0.32 | $4,507,500 | 2 / 2 |
| 2026-10-25 | $-0.32 | $4,507,500 | 3 / 2 |
| 2026-10-26 | $-0.32 | $4,507,500 | 3 / 3 |
| 2026-10-27 | $-0.32 | $4,507,500 | 3 / 3 |
| 2026-10-28 | $-0.32 | $4,507,500 | 3 / 3 |
| 2026-10-29 | $-0.32 | $4,507,500 | 3 / 3 |
| 2026-10-30 | $-0.32 | $4,507,500 | 3 / 3 |
| 2026-10-31 | $-0.32 | $4,507,500 | 3 / 3 |
| 2026-11-01 | $-0.32 | $4,507,500 | 3 / 3 |
| 2026-11-02 | $-0.32 | $4,507,500 | 3 / 3 |
| 2026-11-03 | $-0.32 | $4,507,500 | 3 / 3 |
| 2026-11-04 | $-0.32 | $4,507,500 | 3 / 3 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.